Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma
Summary. Background: Hepatocellular carcinoma (HCC) is an increasing problem worldwide. Determining a prognosis is important for the management of HCC. Aim: We aimed to investigate the impact of interleukin (IL)-29, galectin-3, leptin, fibronectin and protease-activated receptor-1 on the prognosis a...
Gespeichert in:
| Datum: | 2023 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
PH Akademperiodyka
2023
|
| Schlagworte: | |
| Online Zugang: | https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-14 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Experimental Oncology |
Institution
Experimental Oncology| _version_ | 1856543497325117440 |
|---|---|
| author | Çavuş, B. Akyuz, F. İliaz, R. Akyuz, U. Duranyıldız, D. Serilmez, M. Tekin, D. Evirgen, S. Karaca, Ç. Demir, K. Beşışık, F. Kaymakoğlu, S. |
| author_facet | Çavuş, B. Akyuz, F. İliaz, R. Akyuz, U. Duranyıldız, D. Serilmez, M. Tekin, D. Evirgen, S. Karaca, Ç. Demir, K. Beşışık, F. Kaymakoğlu, S. |
| author_sort | Çavuş, B. |
| baseUrl_str | |
| collection | OJS |
| datestamp_date | 2023-10-11T16:43:26Z |
| description | Summary. Background: Hepatocellular carcinoma (HCC) is an increasing problem worldwide. Determining a prognosis is important for the management of HCC. Aim: We aimed to investigate the impact of interleukin (IL)-29, galectin-3, leptin, fibronectin and protease-activated receptor-1 on the prognosis and diagnosis of patients with HCC. Materials and Methods: 60 HCC patients (75% male) and 20 healthy volunteers (70% male) were enrolled in this prospective study. Serum samples were obtained during the first admission before any adjuvant or metastatic treatments were administered. Serum biomarkers were determined using ELISA kits. Results: All patients had cirrhosis, and the Child — Pugh stages were as follows: 61.5% Child — Pugh A, 35.9% Child — Pugh B and 2.6% Child — Pugh C (61.7% hepatitis B virus, 11.7% hepatitis C virus, 6.7% hepatitis B virus + hepatitis C virus, 11.7% alcoholic and 8.3% cryptogenic). Fifty-three percent of the HCC patients died within a median of 7.5 months. The mean serum level of IL-29 in patients with HCC was higher than that in the control group (32.55 pg/ml vs 11.46 pg/ml, p < 0.015). Galectin-3 levels were significantly higher in the HCC group (6.7 ng/ml vs 1.38 ng/ml, p < 0.001). Fibronectin levels were higher in the control group than in the HCC group (260 635 ng/ml vs 257 353 ng/ml). However, the mean protease-activated receptor-1 and leptin levels were similar between the two groups (p > 0.05). The biomarkers were divided into two groups according to their median level. In the log rank analysis, biomarkers had no effect on survival (p > 0.05). Conclusions: IL-29 and galectin-3 levels were significantly higher in HCC patients. Although IL-29 and galectin-3 can be used as diagnostic markers for HCC, they had no prognostic value in HCC patients. |
| first_indexed | 2025-07-17T12:16:09Z |
| format | Article |
| id | oai:ojs2.ex.aqua-time.com.ua:article-177 |
| institution | Experimental Oncology |
| language | English |
| last_indexed | 2025-07-17T12:16:09Z |
| publishDate | 2023 |
| publisher | PH Akademperiodyka |
| record_format | ojs |
| spelling | oai:ojs2.ex.aqua-time.com.ua:article-1772023-10-11T16:43:26Z Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma Çavuş, B. Akyuz, F. İliaz, R. Akyuz, U. Duranyıldız, D. Serilmez, M. Tekin, D. Evirgen, S. Karaca, Ç. Demir, K. Beşışık, F. Kaymakoğlu, S. biomarkers, hepatocellular carcinoma, prognosis biomarkers, hepatocellular carcinoma, prognosis Summary. Background: Hepatocellular carcinoma (HCC) is an increasing problem worldwide. Determining a prognosis is important for the management of HCC. Aim: We aimed to investigate the impact of interleukin (IL)-29, galectin-3, leptin, fibronectin and protease-activated receptor-1 on the prognosis and diagnosis of patients with HCC. Materials and Methods: 60 HCC patients (75% male) and 20 healthy volunteers (70% male) were enrolled in this prospective study. Serum samples were obtained during the first admission before any adjuvant or metastatic treatments were administered. Serum biomarkers were determined using ELISA kits. Results: All patients had cirrhosis, and the Child — Pugh stages were as follows: 61.5% Child — Pugh A, 35.9% Child — Pugh B and 2.6% Child — Pugh C (61.7% hepatitis B virus, 11.7% hepatitis C virus, 6.7% hepatitis B virus + hepatitis C virus, 11.7% alcoholic and 8.3% cryptogenic). Fifty-three percent of the HCC patients died within a median of 7.5 months. The mean serum level of IL-29 in patients with HCC was higher than that in the control group (32.55 pg/ml vs 11.46 pg/ml, p < 0.015). Galectin-3 levels were significantly higher in the HCC group (6.7 ng/ml vs 1.38 ng/ml, p < 0.001). Fibronectin levels were higher in the control group than in the HCC group (260 635 ng/ml vs 257 353 ng/ml). However, the mean protease-activated receptor-1 and leptin levels were similar between the two groups (p > 0.05). The biomarkers were divided into two groups according to their median level. In the log rank analysis, biomarkers had no effect on survival (p > 0.05). Conclusions: IL-29 and galectin-3 levels were significantly higher in HCC patients. Although IL-29 and galectin-3 can be used as diagnostic markers for HCC, they had no prognostic value in HCC patients. Summary. Background: Hepatocellular carcinoma (HCC) is an increasing problem worldwide. Determining a prognosis is important for the management of HCC. Aim: We aimed to investigate the impact of interleukin (IL)-29, galectin-3, leptin, fibronectin and protease-activated receptor-1 on the prognosis and diagnosis of patients with HCC. Materials and Methods: 60 HCC patients (75% male) and 20 healthy volunteers (70% male) were enrolled in this prospective study. Serum samples were obtained during the first admission before any adjuvant or metastatic treatments were administered. Serum biomarkers were determined using ELISA kits. Results: All patients had cirrhosis, and the Child — Pugh stages were as follows: 61.5% Child — Pugh A, 35.9% Child — Pugh B and 2.6% Child — Pugh C (61.7% hepatitis B virus, 11.7% hepatitis C virus, 6.7% hepatitis B virus + hepatitis C virus, 11.7% alcoholic and 8.3% cryptogenic). Fifty-three percent of the HCC patients died within a median of 7.5 months. The mean serum level of IL-29 in patients with HCC was higher than that in the control group (32.55 pg/ml vs 11.46 pg/ml, p < 0.015). Galectin-3 levels were significantly higher in the HCC group (6.7 ng/ml vs 1.38 ng/ml, p < 0.001). Fibronectin levels were higher in the control group than in the HCC group (260 635 ng/ml vs 257 353 ng/ml). However, the mean protease-activated receptor-1 and leptin levels were similar between the two groups (p > 0.05). The biomarkers were divided into two groups according to their median level. In the log rank analysis, biomarkers had no effect on survival (p > 0.05). Conclusions: IL-29 and galectin-3 levels were significantly higher in HCC patients. Although IL-29 and galectin-3 can be used as diagnostic markers for HCC, they had no prognostic value in HCC patients. PH Akademperiodyka 2023-05-31 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-14 10.32471/exp-oncology.2312-8852.vol-42-no-3.15125 Experimental Oncology; Vol. 42 No. 3 (2020): Experimental Oncology; 208-214 Експериментальна онкологія; Том 42 № 3 (2020): Експериментальна онкологія; 208-214 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-42-no-3 en https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-14/2020-3-14 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/ |
| spellingShingle | biomarkers hepatocellular carcinoma prognosis Çavuş, B. Akyuz, F. İliaz, R. Akyuz, U. Duranyıldız, D. Serilmez, M. Tekin, D. Evirgen, S. Karaca, Ç. Demir, K. Beşışık, F. Kaymakoğlu, S. Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| title | Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| title_alt | Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| title_full | Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| title_fullStr | Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| title_full_unstemmed | Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| title_short | Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| title_sort | assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma |
| topic | biomarkers hepatocellular carcinoma prognosis |
| topic_facet | biomarkers hepatocellular carcinoma prognosis biomarkers hepatocellular carcinoma prognosis |
| url | https://exp-oncology.com.ua/index.php/Exp/article/view/2020-3-14 |
| work_keys_str_mv | AT cavusb assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT akyuzf assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT iliazr assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT akyuzu assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT duranyıldızd assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT serilmezm assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT tekind assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT evirgens assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT karacac assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT demirk assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT besısıkf assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma AT kaymakoglus assessmentofprognosticanddiagnosticvalueofsomebiomarkersinhepatocellularcarcinoma |